Beijing Avistone Biotechnology Co Ltd has gained approval from the Chinese National Medical Products Administration to extend the application of vebreltinib for treating adult patients

Hyundai Bioscience made headlines on April th with its breakthrough announcement regarding the development of an oral anticancer drug targeting patients with intractable cancers

Apollomics Inc has announced a significant development regarding vebreltinib in China The National Medical Products Administration has granted approval to Avistone Biotechnology Co Ltd

Biolojic Design a biotech company specializing in AIdriven antibody innovation announced that Nektar has exercised its license option to develop a program resulting from their collaborative research started in

Amneal Pharmaceuticals Inc has unveiled its Over the Counter Naloxone Hydrochloride Nasal Spray USP mg after securing Abbreviated New Drug Application approval from the US Food and Drug Administration

Junshi Biosciences a leading biopharmaceutical company dedicated to innovative therapies has announced the acceptance of its New Drug Application by the Drug Office of the Hong Kong Special Administrative Region This NDA relates to toripalimab proposed for use in combination

PRISM BioLab Co Ltd a leading discovery and development biotechnology company designing small molecule inhibitors of proteinprotein interaction targets today announced that it has entered into a targetexclusive research and licensing agreement with ONO PHARMACEUTICAL CO LTD

Medivir AB a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need announced today that its selective cathepsin K inhibitor MIV has been granted

Our customers depend on the high performance and reliability of the plates used in their highthroughput processes However increased throughput results in a higher carbon footprint

Alkermes plc today announced initiation of the Vibrance study a phase clinical trial evaluating the safety and efficacy of ALKS compared to placebo in patients with narcolepsy type ALKS is the companys novel

Atom Bioscience a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases has begun enrolling patients

Cullinan Therapeutics Inc a biopharmaceutical company focused on modalityagnostic targeted therapies today announced that clinical data from its Phase trial of CLN in patients with advanced solid tumors